Lead Plaintiff Deadline is November 19, 2018     

NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Cocrystal Pharma, Inc. (f/k/a BioZone Pharmaceuticals, Inc.) (“Cocrystal” or the “Company”) (NASDAQ: COCP) on behalf of shareholders who purchased or otherwise acquired Cocrystal and/or BioZone securities between September 23, 2013 to September 7, 2018, inclusive (the “Class Period”).

Investors who have incurred losses in the shares of Cocrystal Pharma, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares of Cocrystal Pharma, Inc. you may, no later than November 19, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Cocrystal Pharma, Inc.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that:

• defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price;
   
• this illicit scheme would result in governmental scrutiny, including from the SEC;
   
• defendants failed to abide by SEC disclosure regulations; and
   
• as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On January 3, 2014, BioZone announced it had finalized its merger with Cocrystal Discovery Inc., forming Cocrystal Pharma on April 15, 2014. Thereafter, Cocrystal Pharma repeatedly assured investors regarding the accuracy of its financial reporting, the disclosure of any material changes to the company's internal control over financial reporting and the disclosure of all fraud.

On September 7, 2018, the U.S. Securities and Exchange Commission (“SEC”) charged 10 individuals, including Cocrystal Pharma Director Phillip Frost and the controlling shareholders of BioZone, for participating in long-running fraudulent schemes that generated over $27 million from unlawful stock sales and caused significant harm to retail investors.

On this news, shares of Cocrystal fell more than 15% over two days to close at $3.16 on September 11, 2018, and now trades at $2.31 per share.

Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

Follow the firm and learn about newly filed cases on Twitter and Facebook.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.